2004


To access this material please log in or register

Register Authorize
2004/№3

Rosuvastin, a new HMG-CoA reductase inhibitor. Preliminary data on efficacy and safety

Susekov A.V.

Keywords:

DOI:

Review provides data of the clinical trials with rosuvastatin, which have demonstrated a potent hypolipidemic effect of this new statin. On completion of the international project GALAXY, it can occupy a leading position in primary and secondary prevention of ischemic heart disease (IHD).

To access this material please log in or register

Register Authorize
Ru En